Save time and jump to the most important pieces.
CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the third quarter ended September 30, 2024 and provided an overview of its recent operational updates. Third Quarter 2024 and Recent Corporate Updates $2 million Non-Dilutive Financing Tranche. In July 2024, the Company announced receipt of a non-dilutive, $2 million tranche in connection with an amendment (the "Amendment") to its existing ex-US royalty financing with R-Bridge Healthcare Fund ("R-Bridge"). The Compa
CHESTERBROOK, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that on October 4, 2024 the Company received notice that the Nasdaq Hearings Panel (the "Panel") had determined to delist the Company's common stock from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with the minimum stockholder's equity requirement under Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard Rule"). As previously disclosed, the Panel had provided the Company until October 2, 2024, to regain comp
CHESTERBROOK, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the "Amendment") to effect a reverse stock split of its common stock at a ratio of 1-for-25. The reverse stock split will become effective at 12:01 a.m. ET on Tuesday, August 13, 2024. Trevena's common stock will continue to be traded on the Nasdaq Capital Market under the symbol "TRVN" and will begin trading on a split-adjusted basis when the market opens on Tu
10-Q - TREVENA INC (0001429560) (Filer)
8-K - TREVENA INC (0001429560) (Filer)
8-K - TREVENA INC (0001429560) (Filer)
Oppenheimer initiated coverage of Trevena with a rating of Market Perform
Oppenheimer initiated coverage of Trevana with a rating of Perform
4 - TREVENA INC (0001429560) (Issuer)
4 - TREVENA INC (0001429560) (Issuer)
4 - TREVENA INC (0001429560) (Issuer)
SC 13G/A - TREVENA INC (0001429560) (Subject)
SC 13G - TREVENA INC (0001429560) (Subject)
SC 13G/A - TREVENA INC (0001429560) (Subject)
Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement Company reported favorable safety and tolerability data from TRV045 POC studies Three abstracts for OLINVYK presented at American Society of Anesthesiologists (ASA) Conference $15 million tranche from ex-US royalty-based financing agreement received in September Company to host conference call today, November 14, 2023 at 8:00 a.m. ET CHESTERBROOK, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for pat
CHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the third quarter ended September 30, 2023, prior to the market open on Tuesday, November 14, 2023. The Company will host a conference call and webcast with the investment community at 8:00 a.m. ET that same day, featuring remarks by Carrie Bourdow, President and Chief Executive Officer, Mark Demitrack, M.D., SVP and Chief Medical Officer, and Barry Shin, SVP and Chief Financial Office
$15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena's partner in China New OLINVYK respiratory data from VOLITION ~200 patient real-world outcomes study, using continuous respiratory monitoring, expected 3Q 2023 Three OLINVYK abstracts accepted for presentation at upcoming American Society of Anesthesiologists Meeting in 4Q 2023 Company to participate in upcoming HC Wainwright conference (September 11-13) Company to Hold Conference Call on Wednesday, September 6 at 8 a.m. Eastern Time to discuss TRV045 Proof-of-Concept Data CHESTERBROOK, Pa., Sept. 06, 2023 (GLOBE NEWSWI
CHESTERBROOK, Pa. , July 20, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Corrigan, M.D. has been appointed to the Company's Board of Directors, effective July 18 2023. "We are pleased to welcome Mark to Trevena's Board of Directors," said Carrie Bourdow, Trevena's President and CEO. "Mark has over 30 years of experience in the life sciences industry and broad neuroscience expertise. He will be an invaluable member of the Board and guide to the management team as we continue to execute on our corporate
Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced the appointment of John M. Limongelli as the Company's Chief Legal Officer effective September 16, 2021. "John's breadth of experience in the biopharma industry, his deep technical acumen, and his expertise at helping build strong corporate practices will be of invaluable benefit to our leadership team," said John Furey, Chief Executive Officer. "As we work to expand our platform to address a variety of solid tumors, John's expertise will be an essential part of the development of these assets." Mr. Limongelli is an accomplished executive officer and lawyer with near
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose sharply in today's pre-market trading after the company announced expanded US FDA approval of ELEVIDYS to Duchenne Muscular Dystrophy patients ages 4 and above. Sarepta Therapeutics shares climbed 35.2% to $166.96 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Spectaire Holdings Inc (NASDAQ:SPEC) rose 110% to $0.7140 in pre-market trading after the company announced a purchase order and delivery of its advanced AireCore units to American Ag Energy. DermTech, Inc. (NASDAQ:DMTK) gained 105.5% to $0.2423 in pre-market trading after declining 19% on Thursday. DermTech recently filed f
Gainers Psyence Biomedical (NASDAQ:PBM) stock moved upwards by 68.1% to $1.0 during Thursday's after-market session. The market value of their outstanding shares is at $13.3 million. Kintara Therapeutics (NASDAQ:KTRA) shares moved upwards by 15.67% to $0.32. The market value of their outstanding shares is at $17.5 million. Talphera (NASDAQ:TLPH) shares rose 12.64% to $0.92. The market value of their outstanding shares is at $15.6 million. Helius Medical Tech (NASDAQ:HSDT) shares moved upwards by 10.11% to $1.06. The market value of their outstanding shares is at $3.1 million. Clover Health Investments (NASDAQ:CLOV) stock rose 9.72% to $1.13. The company's market cap stands at $561.0 mil